Outlook Therapeutics

2024 was a challenging year for the biopharma industry, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds to thousands of jobs. Cassava Sciences announced layoffs of 10 employees, 33% of its workforce, following a failed Phase III trial for its Alzheimer's drug. CytomX Therapeutics cut 40% of its staff to focus on clinical programs. Velia, a San Diego biotech, is shutting down, affecting 47 employees. Regeneron's acquisition of Oxular led to layoffs, with no Oxular employees joining Regeneron. Javara, Ring Therapeutics, Outlook Therapeutics, Editas, Bavarian Nordic, BenevolentAI, Chroma Medicine and Nvelop Therapeutics, Cellectar Biosciences, Carisma Therapeutics, Belharra Therapeutics, National Resilience, AmplifyBio, Agenus, Alligator Bioscience, Idorsia Pharmaceuticals, Kronos Bio, Novartis, Recursion Therapeutics, Medigene, Alector, Bristol Myers Squibb, Sonata Therapeutics, 23andMe, Johnson & Johnson, Merck, Gilead Sciences, Adaptimmune, Sensei Biotherapeutics, Marinus Pharmaceuticals, Orna Therapeutics, Thermo Fisher Scientific, Charles River Laboratories, Aurinia Pharmaceuticals, Viracta Therapeutics, Astellas Gene Therapies, Sana Biotechnology, Sage Therapeutics, Compass Pathways, Spero Therapeutics, ICON, Pfizer, Takeda, SalioGen Therapeutics, Evonik, Medtronic, CareFusion Resources, Turnstone Biologics, Leo Pharma, Astellas Pharma, Prime Medicine, Kaléo, Stryker, Relay Therapeutics, ImmunityBio, Shattuck Labs, Inventprise, bluebird bio, Athira Pharma, AGC Biologics, Oncternal Therapeutics, Biosense Webster, Vesigen Therapeutics, Connect Biopharma, BioMarin, IN8bio, Edwards Lifesciences, DermTech, Repare Therapeutics, Genentech, Tome Biosciences, Aadi Bioscience, Lykos Therapeutics, Evotec, Galera Therapeutics, Grail, Ovid Therapeutics, Lexicon Pharmaceuticals, Acelyrin, Boundless Bio, FibroGen, Ajinomoto Bio-Pharma Services, AN2 Therapeutics, Entero Therapeutics, Precigen, Sumitomo Pharma America, uniQure, Vir Biotechnology, Arbutus Biopharma, HilleVax, and Bayer also announced significant layoffs, reflecting a tough year for the industry.

The Age-related Vision Dysfunction Market report by DelveInsight provides insights into treatment trends, epidemiology, and market forecasts from 2020 to 2034. It highlights key companies and therapies, including bevacizumab and Rocklatan, and discusses the prevalence of conditions like AMD, glaucoma, and cataracts in the US, EU4, UK, and Japan.

Outlook Therapeutics' stock rose 18.24% despite a $75.4M net loss for FY2024, with loss per share decreasing to $4.06. The company's new drug, LYTENAVA™, expected FDA approval by H2 2025, is seen as a cheaper, effective treatment for wet AMD, with analysts predicting a +1525.21% upside.

The Age-related Vision Dysfunction Market report by DelveInsight forecasts trends, treatments, and epidemiology from 2020 to 2034, highlighting key companies and therapies. It covers conditions like AMD, glaucoma, and diabetic retinopathy, emphasizing the need for innovative treatments in aging populations.

LYTENAVA received EU and UK marketing authorization for wet AMD treatment in 2024, with a potential 2025 launch in the UK and Germany. Despite not meeting non-inferiority in the NORSE EIGHT trial, ONS-5010 showed vision improvement and safety. Outlook Therapeutics plans a BLA resubmission in 2025 and collaborates with Cencora for global commercialization.

Outlook Therapeutics released its annual Form 10-K, highlighting a net loss of $(75.4) million and plans for ONS-5010/LYTENAVA's EU and UK launch in 2025. The company faces financial challenges, regulatory risks, and the need for additional funding to support operations and product development.

LYTENAVA™, the first approved ophthalmic bevacizumab for wet AMD in the EU and UK, anticipates a commercial launch in H1 2025. Outlook Therapeutics reported a $75.4M net loss for FY2024, with plans for NORSE EIGHT trial data in January 2025 and BLA resubmission in Q1 2025. The company is preparing for LYTENAVA™'s launch in Europe and potential US FDA approval in H2 2025.

Outlook Therapeutics reported a $75.4M net loss for FY2024, with $14.9M cash as of September 30, 2024. LYTENAVA™, approved in EU and UK for wet AMD, plans H1 2025 launch. NORSE EIGHT efficacy data expected January 2025; BLA resubmission targeted for Q1 2025.

NICE recommends LYTENAVA™ (bevacizumab gamma) for wet AMD treatment, marking the first positive reimbursement decision worldwide. LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for wet AMD in the EU and UK, with a planned launch in H1 2025. The decision is expected to benefit 40,000 new wet AMD patients annually in the UK.

Outlook Therapeutics, Inc. announces Russell Trenary's resignation as CEO, with Lawrence Kenyon appointed as Interim CEO. The company plans to resubmit the BLA for ONS-5010 in Q1 2025 and launch LYTENAVA™ in Europe in H1 2025.